Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

NCT03588299 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
11
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bayer

Collaborators